Get the Stockscreener App
2.37
2.07%
-0.05
Matinas Biopharma Holdings Inc stock is traded at $2.37, with a volume of 24,506.
It is down -2.07% in the last 24 hours and down -4.30% over the past month.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. The company's lead anti-fungal product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. Its product candidates also comprise MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey.
See More
Previous Close:
$2.42
Open:
$2.48
24h Volume:
24,506
Relative Volume:
0.22
Market Cap:
$2.32M
Revenue:
$1.10M
Net Income/Loss:
$-11.23M
P/E Ratio:
-1.1704
EPS:
-2.025
Net Cash Flow:
$-6.61M
1W Performance:
-17.42%
1M Performance:
-4.30%
6M Performance:
-69.90%
1Y Performance:
-90.76%
1-Day Range:
$2.36
$2.50
1-Week Range:
$2.36
$2.85
52-Week Range:
$2.2577
$28.35
Matinas Biopharma Holdings Inc Stock (MTNB) Company Profile
Name
Matinas Biopharma Holdings Inc
Sector
Industry
Phone
908-443-1860
Address
1545 Route 206 South, Suite 302, Bedminster, NJ
Compare MTNB vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTNB
Matinas Biopharma Holdings Inc
|
2.37 | 2.32M | 1.10M | -11.23M | -6.61M | -2.025 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Matinas Biopharma Holdings Inc Stock (MTNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-26-20 | Resumed | Piper Sandler | Overweight |
| Jan-27-20 | Initiated | Piper Sandler | Overweight |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Jan-09-20 | Initiated | Aegis Capital | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Matinas Biopharma Holdings Inc Stock (MTNB) Latest News
Stock splits calendar for: - Yahoo Finance Australia
Matinas BioPharma Holdings, Inc.: Dividend historical data and projections - marketscreener.com
MTNB Q4 2024 Earnings: Narrower-Than-Expected Loss Meets Negative Stock ReactionProfit Inflection Point - https://www.dars.gov.et/
Stock splits calendar for: - Yahoo Finance Australia
Matinas BioPharma Holdings, Inc. Revenue Breakdown – GETTEX:6LJ - TradingView
Enterprise value to revenue forward of Matinas BioPharma Holdings, Inc. – FWB:6LJ - TradingView
Book value per share of Matinas BioPharma Holdings, Inc. – MUN:6LJ - TradingView
Form DEF 14A Matinas BioPharma Holdings Inc For: 29 September By Investing.com - Investing.com Canada
Form DEF 14A Matinas BioPharma Holdings Inc For: 29 September By Investing.com - Investing.com UK
Stock splits calendar for: - Yahoo Finance Singapore
Stock splits calendar for: - Yahoo Finance Singapore
Matinas BioPharma (MTNB) Climbs 8.4% as Sub-$1 Biotech Pushes Toward $0.18 ResistanceInitial Balance - siam.in
Matinas BioPharma (MTNB) Climbs 8.4% as Sub-$1 Biotech Pushes Toward $0.18 ResistancePre-Earnings Momentum - dars.gov.et
Matinas BioPharma announces one-for-fifteen reverse stock split approval By Investing.com - Investing.com India
Matinas BioPharma announces one-for-fifteen reverse stock split approval - Investing.com
Matinas BioPharma announces one-for-fifteen reverse stock split approval By Investing.com - Investing.com Australia
Form 8K Matinas BioPharma Holdings Inc For: 16 September By Investing.com - Investing.com Nigeria
Matinas BioPharma announces one-for-fifteen reverse stock split approval By Investing.com - Investing.com Canada
Form 8K Matinas BioPharma Holdings Inc For: 16 September By Investing.com - Investing.com Canada
Matinas BioPharma to implement 1-for-15 reverse stock split effective Sept. 28, 2026 - TradingView
Form 8K Matinas BioPharma Holdings Inc For: 16 September By Investing.com - Investing.com UK
A first commercial hydrogen deal covers up to 1,000 kilograms a day from GH Power’s facility. - Stock Titan
Price to sales forward of Matinas Biopharma Holdings, Inc. – BOATS:MTNB - TradingView
Matinas BioPharma Share PriceMTNB, RNS News, Articles, Quotes, & Charts (OTCMKTS:MTNB) - Proactive financial news
Matinas Biopharma (MTNB) Holds Steady at $0.18 as Key Support HoldsDark Pool Prints - careplusvn.com
Matinas BioPharma Receives New NYSE American Delisting Risk on Equity Shortfall - minichart.com.sg
Matinas BioPharma Faces NYSE American Compliance Challenges - TipRanks
Matinas BioPharma Receives NYSE American Noncompliance Notice for Continued Listing Standards - Quiver Quantitative
Matinas BioPharma Received Notice of Noncompliance - tradingview.com
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards - Yahoo Finance
Matinas (MTNB) Results Review: EPS Lands Above Forecast in the Latest Reading; Closing Move: Shares Finish 1.16% Down at the ClosePerformance Review - vinanet.vn
Hydrogen startup GH Power lines up deal with Matinas BioPharma (NYSE: MTNB) - stocktitan.net
Matinas (MTNB) Session: Finishes 1.16% Down at $0.20 on the Day; Levels: the Near-Term Reference Band Stretches From $0.19 to $0.21 in the Current UpdateWave Equality - vinanet.vn
Matinas (MTNB) Q4 2024 Earnings: EPS Beats Its Estimate at the Close; Market Response: Shares Move 8.93% Higher in the Latest ReadingShare Repurchase Impact - vinanet.vn
Matinas (MTNB) Q4 2024 Earnings: EPS Beats Its Estimate at the Close; Market Response: Shares Move 8.93% Higher in the Latest ReadingWeak Earnings Momentum - vinanet.vn
Matinas (MTNB) Q4 2024 Earnings: EPS Beats Its Estimate at the Close; Market Response: Shares Move 8.93% Higher in the Latest ReadingProduct Revenue Analysis - vinanet.vn
Matinas (MTNB) Q4 2024 Earnings: EPS Beats Its Estimate at the Close; Market Response: Shares Move 8.93% Higher in the Latest ReadingEarnings Outlook Update - careplusvn.com
Matinas (MTNB) Q4 2024 Earnings: EPS Beats Its Estimate at the Close; Market Response: Shares Move 8.93% Higher in the Latest ReadingBuyback Announcement Report - careplusvn.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Top Premarket Decliners - marketscreener.com
Matinas (MTNB) Results Review: The Bottom-Line Figure Outpaces Its Comparison for the Current Session; Market Response: The Stock Loses 8.33%Earnings Trend Analysis - vinanet.vn
Matinas Biopharma Holdings Inc. (MTNB) Q4 2024 Earnings: Narrower Loss of -$0.82 Beats Estimates as Clinical Pipeline AdvancesRevenue Warning Signal - vinanet.vn
Matinas Biopharma Holdings Inc. (MTNB) Q4 2024 Earnings: Narrower Loss of -$0.82 Beats Estimates as Clinical Pipeline AdvancesRevenue Surprise History - dars.gov.et
Matinas Biopharma Holdings Inc. (MTNB) Q4 2024 Earnings: Narrower Loss of -$0.82 Beats Estimates as Clinical Pipeline AdvancesReturn On Equity - dars.gov.et
Matinas BioPharma (MTNB) holder Adam Stern details 9.99% stake and new warrants - Stock Titan
Matinas Biopharma (MTNB) Slips 2.6% to $0.26 as Micro-Cap Biotech Tests SupportBreakout Stock Alerts - careplusvn.com
Matinas Biopharma (MTNB) Slips 2.6% to $0.26 as Micro-Cap Biotech Tests SupportZero Gamma Level - vinanet.vn
US Micro Cap StocksInvest from India - INDmoney
Matinas Biopharma Holdings Inc Stock (MTNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):